高血压及合并糖尿病患者血浆内脂素与SOD的相关性

Association Investigation of Plasma Visfatin and SOD in Hypertensive Patients and Hypertensive Diabetic Patients

【目的】测定高血压和高血压合并糖尿病患者血浆内脂素(visfatin)和超氧化物歧化酶(SOD)水平的变化,并探讨两者在所研究人群的相关情况。【方法】本横断面研究共纳入88人,分为对照组(n=26)、高血压组(n=31)和高血压合并糖尿病组(n=31)。参与者的血压均由水银式血压计测定。人群血浆的visfatin浓度和SOD活性应用酶联免疫吸附法测定,而其血糖、糖化血红蛋白A1C(GHb A1c)和血脂有相应方法测定。【结果】单纯高血压组血清总胆固醇(TC)和体质量指数(BMI)较对照组显著性升高(P<0.05),而高血压合并糖尿病组血清TC、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、BMI和腰围(WC)均较对照组显著性升高(P<0.05)。单纯高血压组和高血压合并糖尿病组血浆visfatin浓度(ng/m L)均较对照组显著升高(57.6±16.0、118.3±21.7 vs 21.4±8.2,P<0.05),而高血压合并糖尿病组较单纯高血压组血浆visfatin浓度(ng/m L)更高,且差异也有显著性(118.3±21.7 vs 57.6±16.0,P<0.05)。单纯高血压组和高血压合并糖尿病组血浆SOD活性(U/m L)较对照组显著性降低(157.1±18.6、145.1±31.4 vs 168.4±23.1,P<0.05),而高血压合并糖尿病组较单纯高血压组血浆SOD活性(U/m L)更低,且差异同样有显著性(145.1±31.4 vs 157.1±18.6,P<0.05)。对整个研究人群进行相关性分析发现,visfatin浓度与SOD活性之间呈显著负相关(r=-0.390,P<0.05)。【结论】单纯高血压和高血压合并糖尿病患者血浆visfatin浓度均较对照组升高,而且在高血压合并糖尿病患者升高更明显,血浆visfatin浓度升高可能与SOD活性的下降有关。

【Objective】 To detect the levels of visfatin and superoxide dismutase（SOD）in plasma of hypertensive and hypertensive diabetic patients.And to explore the correlation between visfatin and SOD in the whole study population. 【Methods】 In this cross-sectional study, eighty-eight cases were enrolled, which were divided into hypertensive group（n = 31）, hypertensive diabetic group（n = 31） and control group（n = 26）. Blood pressure was obtained from each participant with mercury sphygmomanometer. The levels of visfatin and SOD were measured by ELISA. Meanwhile, the levels of blood glucose, glycosylated hemoglobin A1C（GHb A1c） and lipid profile were detected. 【Results】 The levels of total cholesterol（TC） and body mass index（BMI） were significantly higher in the hypertensive group than those in control group（P〈0.05）. The levels of TC, low density lipoprotein cholesterol（LDL-C）, triglyceride（TG）, BMI, waist circumference were significantly higher in the hypertensive diabetic group than those in control group（P〈0.05）. The mean plasma concentration of visfatin in both hypertensive diabetic group and only hypertensivegroup was significantly increased compared to that in the normal group（57.6 ± 16.0,118.3 ± 21.7, vs 21.4 ± 8.2 ng / m L,P〈0.05）.While the mean plasma concentration of visfatin in the hypertensive diabetic group was also significantly increased compared to that in the hypertensive group（118.3 ± 21.7 vs 57.6 ± 16.0 ng / m L,P〈0.05）. The plasma SOD activity in both hypertensive diabetic group and hypertensive group was significantly decreased compared to that in the normal group（157.1 ± 18.6,145.1 ± 31.4, vs 168.4 ± 23.1U / m L,P〈0.05）. While the plasma SOD activity in hypertensive diabetic group was significantly decreased compared to the hypertensive group（145.1 ± 31.4 vs 157.1 ± 18.6 U / m L,P〈0.05）. There was a significantly negative correlation between plasma visfatin concentration and SOD activity in the whole study population（r =-0.390, P〈0.05）. 【Conclusion】 The plasma concentration of visfatin is increased in both hypertensive and hypertensive diabetic patients, and more increased in hypertensive diabetic patients.Increased visfatin concentration may be associated with to the reduction of SOD activity.